AUSTRALIAN Public Assessment Reports (AusPARs) have been generated for AstraZeneca's new chemical entity Zurampic (lesinurad) an adjunctive therapy for gout, Novartis' sacubitril/valsartan salt complex chronic heart failure treatment and Roche Products' Actemra, an adjunctive therapy for rheumatoid arthritis.
Visit www.tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 16